Lemborexant
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
- Lemborexant
- Lemborexant: From an Unrecorded Original Indication to Sleep Disorder, Initiating and Maintaining Sleep
Lemborexant: From an Unrecorded Original Indication to Sleep Disorder, Initiating and Maintaining Sleep
One-Sentence Summary
Lemborexant (DrugBank DB11951) has no recorded original approved indication or marketing license in this dataset, and its mechanism of action is not formally documented here. The TxGNN model’s top prediction is Sleep Disorder, Initiating and Maintaining Sleep (insomnia), a direction already backed by 1 registered clinical trial and 20 publications, several of which are completed Phase 3 RCTs.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no license records or original indication data in this dataset |
| Predicted New Indication | Sleep Disorder, Initiating and Maintaining Sleep |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L1 (≥2 completed Phase 3 RCTs identified in literature) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, a formal mechanism-of-action record is not available for this candidate in the dataset. However, the collected literature evidence consistently and independently describes lemborexant as a dual orexin receptor antagonist (DORA), acting on OX1R and OX2R to suppress wake-promoting neurotransmission and facilitate sleep onset and maintenance (e.g., PMID 35972717 “Orexin Receptor Antagonists and Insomnia”; PMID 37086045 “The orexin story and orexin receptor antagonists for the treatment of insomnia”; PMID 32096020 “Lemborexant: First Approval”).
Because this mechanism is inherently sleep-promoting, the TxGNN-predicted indication — Sleep Disorder, Initiating and Maintaining Sleep (i.e., insomnia) — is directly consistent with the pharmacology reported in the literature evidence, rather than representing a distant or unexpected repurposing target.
It is worth noting that this appears less like a novel “repurposing” signal and more like the model correctly recovering the drug’s core, well-established pharmacological use from the knowledge graph — multiple completed Phase 3 RCTs (e.g., the SUNRISE-2 trial) already directly evaluate lemborexant for this exact indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06928766 | Phase 2 | Not Yet Recruiting | 15 | Double-blind, placebo-controlled RCT of eszopiclone vs. lemborexant in obstructive sleep apnoea (OSA) patients with a low arousal threshold who have difficulty maintaining or falling asleep (COMISA population) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31880796 | 2019 | RCT (Phase 3) | JAMA Network Open | Lemborexant vs. placebo and zolpidem ER in older adults with insomnia disorder |
| 33636648 | 2021 | RCT (Phase 3, SUNRISE-2) | Sleep Medicine | Long-term (12-month) effectiveness and safety of lemborexant in adults with insomnia disorder |
| 32585700 | 2020 | RCT (Phase 3, SUNRISE-2) | Sleep | Long-term efficacy and tolerability of lemborexant vs. placebo in insomnia disorder |
| 39879708 | 2025 | Post-hoc RCT analysis | Sleep Medicine | Effect of lemborexant on sleep architecture in patients with insomnia and mild OSA (COMISA) |
| 39120786 | 2024 | Pooled trial analysis | Drugs & Aging | Efficacy and safety of lemborexant in older adults across three clinical trials |
| 34121443 | 2021 | Network meta-analysis | J Managed Care Spec Pharm | Comparative efficacy of lemborexant vs. other insomnia treatments |
| 36701954 | 2023 | Systematic review / NMA | Sleep Medicine Reviews | Efficacy and tolerability ranking of pharmacological insomnia treatments (20 drugs) |
| 35843245 | 2022 | Systematic review / NMA | Lancet | Comparative effectiveness of pharmacological interventions for insomnia disorder |
| 32096020 | 2020 | Review | Drugs | Lemborexant (DAYVIGO) first approval profile — mechanism, development, indication |
| 35972717 | 2022 | Review | Current Psychiatry Reports | Review of orexin receptor antagonists, including lemborexant, for insomnia |
US Market Information
Currently no marketed authorization records are available — 0 NDAs on file and market status is recorded as Not Marketed in this dataset.
Safety Considerations
Please refer to the package insert for safety information. No key warnings, contraindications, or drug-drug interaction data are currently available in this dataset (DDI query returned no results). This also constitutes a Blocking-severity data gap (TFDA label warnings/contraindications), which prevents a formal S1 safety pre-assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: Literature evidence strongly and consistently supports lemborexant’s efficacy for this exact indication (multiple completed Phase 3 RCTs), but a Blocking data gap on label warnings/contraindications means initial safety screening (S1) cannot be completed, and the drug currently has no marketing license on record.
To proceed, the following is needed:
- TFDA/FDA package insert (warnings, precautions, contraindications) — remediation source already identified (TFDA official site, PDF parsing)
- Confirmed drug-drug interaction (DDI) data
- Formal mechanism-of-action record via DrugBank API
- Clarification of current marketing/licensing status in the target jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.